A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

Inclusion criteria

• Participant must be 18 to 55 years of age inclusive.

• Participants who are overtly healthy Japanese as determined by medical evaluation.
• Body mass index (BMI) within the range 18 - 29.9 kg/m² (inclusive).
• Male participants must agree to use specified contraception during the study and for at least 90 days plus 5 half-lives after.
• Female participants must be a Woman of Nonchildbearing Potential (WONCBP).
• Capable of giving signed informed consent.
• Willing to comply with the requirements and restrictions listed in the protocol.

Exclusion criteria

• Any medical disorder, condition, or history that would impair participation.

• Known hypersensitivity to the study drug or its excipients.
• Known disorders with increased bleeding risk or known congenital/acquired coagulation disorders.
• Use of prescription drugs, over-the-counter drugs, or herbal products within 14 days or 5 half-lives before the study.
• Clinically relevant findings in the ECG, such as a QTcF over 450 msec.
• Systolic blood pressure below 90 mmHg or above 140 mmHg at screening and admission.
• Diastolic blood pressure below 40 mmHg or above 90 mmHg at screening and admission.
• Positive results for Hepatitis B, Hepatitis C, or HIV.
• Positive drug screening, alcohol breath test, or urine cotinine test.
• Clinically relevant deviations of the screened laboratory parameters from reference ranges at the screening visit.
• Positive pregnancy test.
• Donation of blood or plasma within specified timeframes before the study.
• Lack of compliance with lifestyle restrictions (e.g., alcohol, specific foods, strenuous activity).
• Previous participation in this or another clinical study within a specified timeframe.